Malaria has been a major global health problem of humans through history and is a leading
cause of death and disease across many tropical and subtropical countries. Over the last …

The development of highly effective and durable vaccines against the human malaria
parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor …

Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …

Background Development of an effective vaccine against the pathogenic blood-stage
infection of human malaria has proved challenging, and no candidate vaccine has affected …

Virus-like particles (VLPs) are non-infectious self-assembling nanoparticles, useful in
medicine and nanotechnology. Their repetitive molecularly-defined architecture is attractive …

Malaria accounts for an enormous burden of disease globally, with Plasmodium falciparum
accounting for the majority of malaria, and P. vivax being a second important cause …

Plasmodium species cause malaria by proliferating in human erythrocytes. Invasion of
immunologically privileged erythrocytes provides a relatively protective niche as well as …

Plasmodium falciparum parasites in the merozoite stage invade human erythrocytes and
cause malaria. Invasion requires multiple interactions between merozoite ligands and …

Abstract Development of a malaria vaccine remains a critical priority to decrease clinical
disease and mortality and facilitate eradication. Accordingly, RTS, S, a protein-subunit …

Highlights•Safety and potency of simian adenovirus vectors is now well established, most
recently in infants.•Viral vectored vaccines are effective against malaria and Ebola in field …